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Carbonic anhydrases (CAs, EC 4.2.1.1) are inhibited by sulfonamides, phenols, and coumarins.
Polyamines such as spermine, spermidine, and many synthetic congeners are described to constitute
a novel class ofCA inhibitors (CAIs), interactingwith the different CA isozymeswith efficiency from the
low nanomolar to millimolar range. The main structure-activity relationship for these CAIs have been
delineated: the length of the molecule, number of amine moieties, and their functionalization are the
main parameters controlling activity. The X-ray crystal structure of the CA II-spermine adduct
allowed understanding of the inhibition mechanism. Spermine anchors to the nonprotein zinc ligand
through a network of hydrogen bonds. Its distal amine moiety makes hydrogen bonds with residues
Thr200 and Pro201, which further stabilize the adduct. Spermine binds differently compared to
sulfonamides, phenols, or coumarins, rendering possible to develop CAIs with a diverse inhibition
mechanism, profile, and selectivity for various isoforms.
Introduction
Polyamines such as spermine and spermidine are small
polycationic aliphatic molecules ubiquitously found in organ-
isms all over the phylogenetic tree (including animals, plants,
fungi, archaea, and some bacteria), functioning in a variety
of biological processes such as regulation of gene expression,
translation, cell proliferation, modulation of cell signaling,
membrane stabilization, and modulation of activities of sev-
eral ion channels.1-5 Being polycations, these molecules bind
to anionic macromolecules such as DNA, RNA, and to some
proteins, their homeostasis being ensured through regula-
tion of biosynthesis, catabolism, and transport.1-5 Polyamine
catabolismwas recently shown toplay adominant role in drug
response, apoptosis, and the response to stressful stimuli
and to contribute to the etiology of several pathological states,
including cancer6 and brain ischemia.7 Thus, there is an
increasing interest in understanding the interaction of such
compounds with various macromolecules (nucleic acids,
structural proteins, or enzymes) and in designing agentswhich
interfere with these processes in order to obtain pharmacolo-
gical agents with a novel mechanism of action.6,7 It has been
also reported recently that the brain levels of some of these
polyamines vary greatly with the age in humans.8 Indeed,
spermine level was shown to be significantly decreased in the
perirhinal cortex and increased in the postrhinal cortex with
age. In the prefrontal cortex, there was age-related decrease in
putrescine, whereas the spermidine and spermine levels were
significantly increased with age. This study8 demonstrated an
age-related, region-specific change in polyamines in memory-
associated structures, suggesting that the polyamine system
dysfunction may contribute to aged-related impairments in
hippocampal neurogenesis, learning, and memory.
Another system which has been shown recently to vary
considerably in the aging brain9,10 is that constituted by the
carbonic anhydrase enzymes (CAs,a EC 4.2.1.1).11,12 Indeed,
these zinc proteins, which catalyze the hydration of carbon
dioxide to bicarbonate and protons,11 are present in high
amounts in the vertebrate brain (several different isoforms of
the 16 described inmammals are present in this organ, among
whichCA II, III, IV,VB,VII, VIII, IX,X,XII, andXIV),12-14
where they play crucial roles in pH homeostasis, which affects
neuronal excitability, neurotransmission, epileptogenesis, and
learning andmemory.12-14 CA inhibitors (CAIs) and also CA
activators (CAAs) have been shown to have profound con-
sequences on brain function under physiological and patho-
physiological conditions.15-17
All CAAs investigated up to now belong to the class
of amino acids and amines.17-21 Considering the possible
involvement of these enzyme modulators in the brain
function,15,16 together with the recently discovered variation
of polyamine concentrations in the aging brain,8wedecided to
investigate whether polyamines such as spermine and spermi-
dine might act as CAAs. CAIs on the other hand belong to
three main classes: (i) sulfonamides (such as acetazolamide 1
or dichlorophenamide 2) andmetal complexing anions,which
coordinate to theZn(II) in tetrahedral or trigonal bipyramidal
geometries of themetal ion,11 (ii) phenols (such as 3),20f which
bind to the zinc-coordinated water molecule/hydroxide ion
from the active site, through a network of two hydrogen
bonds,20f ,22 and (iii) the very recently reported third class of
effective CAIs, the coumarins and thiocoumarins,23 which
have an inhibition mechanism indipendent of Zn(II), as they
†The coordinates of the hCA II-spermine adduct have been deposited
in PDB, ID code 3KWA.
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bind (in hydrolyzed form) in the same active site region as
the activators.23 Because they do not have proton-shuttling
moieties in theirmolecule, they occlude the active site entrance
and constitute potent and isoform-selective (in some cases)
inhibitors.23 Here we report a fourth class of CAmodulators,
the polyamines, which unexpectedly, do not act as activators
but as inhibitors of these enzymes through a novel inhibition
mechanism.
Results and Discussion
Chemistry and CA Inhibition.Activators of the CAs belong
to the amine and amino acid class. Both aliphatic and aromatic
amines or aminoacidswere shown to effectively activate allCA
isozymes present in mammals, i.e., CA I-CA XV.17-20 By
means of their protonatable groups, usually of the primary or
secondary amine type, the CAAs facilitate the deprotonation
of the water bound to the Zn(II) ion within the CA active site,
with formation of the nucleophilically active species of the
enzyme, with hydroxide coordinated to Zn(II) as the fourth
ligand. CAIs known to date either directly bind to the Zn(II)
ion from the enzyme active site (sulfonamides, inorganic
complexing anions) or anchor to the nonprotein zinc ligand,
a water molecule/hydroxide ion.11 Only phenol 3 is known to
inhibitCAs in thisway (Chart 1).20f ,22Recently, a thirdbinding
mode for CAIs has been reported by our group. Coumarins
and thiocoumarins (in hydrolyzed form) and lacosamide bind
at the entrance of the CA active site and occlude it, this
inhibition mode being thus independent of the metal ion.23
Considering our interest in modulators (activators/
inhibitors) of CA activity, and based on the rationale dis-
cussed above, polyamines such as spermine 4, spermidine 5,
as well as many other synthetic structurally related com-
pounds (which as outlined in the introduction, have impor-
tant biological functions),1-3 of types 6-21, were assayed for
their interaction with the 13 catalytically active human/
murine (h/m) CA isoforms, hCA I-hCA XII, mCA XIII,
hCA XIV, and mCA XV (Table 1). Our working hypothesis
was that similar to other investigated amines (histamine,
L-adrenaline, various heterocyclic or aromatic amines pos-
sessing aminomethyl or aminoethyl moieties).17-20 the poly-
cationic amines 4-21 may activate these CAs. Indeed,
amines 4-9 possess several primary/secondary/tertiary
amine functionalities in their molecules, with pKas in the
range of 7.9-10.9 (at least for derivatives 4 and 5),1 which in
principle can shuttle protons from the zinc-bound water
molecule to the external of the active site cavity, with
formation of the nucleophilic species of CA, similarly to
previously investigated amine/amino acid CAA.17-20
Synthetic, commercially available polyamines, such as the
hexamethyl-derivative of trien 8, 1,5-hexanediamine 9, and
its shorter analogue cadaverine 10 (1,5-pentanediamine),
together with diethylenetriamine 11, ethylenediamine, and
its 1-naphthylderivative 12, were also included in this study
in order to investigate whether the length of the chain, the
substitution pattern at the amino groups, and the number of
heteroatoms present in the chain influence the binding to the
enzymes (Chart 2). A commercially available monoderiva-
tized spermine derivative, 1-naphthyl-acetamido-spermine
13, has also been investigated (this synthetic analogue of
the Joro spider toxin blocks calcium permeable AMPA
receptors having important effects on dendrite forma-
tion by cerebellar Purkinje cells, among others),21 together
with previously prepared compounds synthesized by us, i.e.,
the polyamine derivatives 14-21, incorporating trifluoro-
acetyl and tert-butyloxycarbonyl (Boc) protecting groups at
the primary and/or secondary amino moieties of spermine
(derivatives 14-16) of the tetramine 6 (derivatives 17 and
18), of trien 7 (derivatives 19 and 20), and of 1-naphthyl-
ethylenediamine 12 (compound 21). In this way, a rather
comprehensive structure-activity relationship (SAR) in-
sight may be gained regarding the interaction of CAs with
this new class of modulators of their activity.
Inhibition data against mammalian CA isozymes CA
I-XV with compounds 1-21 are shown in Table 1. As seen
from these data, polyamines 4-21 do not exhibit CA acti-
vating properties against the investigated CA isoforms but,
similarly to sulfonamides 1 and 2, or phenol 3, they show
significant CA inhibitory properties. It should be noted that
among polyamines investigated here, only ethylenediamine
(H2NCH2CH2NH2) did not possess important CA inhibi-
tory properties against any CA isoform (KI > 500 μM, data
not shown) and this compound will be not included in the
subsequent discussion. The following SAR has been drawn
from data of Table 1 for this new class of CAIs:
(i) Spermine 4 was a low nanomolar inhibitor (KI of
10 nM) against hCA IV, a transmembrane isoform
involved in many important physiological processes24
and also effectively inhibited (with inhibition constants
in the range of 0.71-0.99 μM) the mitochondrial
isoforms hCA VA and hCA VB, the secreted one
hCA VI, as well as the cytosolic hCA VII and trans-
membrane hCA XIV isozymes, which are present in
high amounts in the human brain.12-14 Three other
CAs, i.e., hCA IX, hCA XII, and mCAXIII, were less
effectively inhibited by spermine, with KIs in the range
of 13.3-27.6 μM, whereas the cytosolic, ubiquitous,
andphysiologicallydominanthCAIIand themembrane-
associated one mCA XV showed KIs in the range
of 74-84 μM with this inhibitor. The least inhibited
isozymes were the cytosolic hCA I and III (KIs of
167-231 μM).
(ii) Spermidine 5, one triamine shorter than 4 (10 carbon/
nitrogen atoms in the scaffold, compared to the 14
ones of spermine), showed a CA inhibition profile
quite distinct from that of spermine 4 (Table 1). hCA
Chart 1. CA Inhibitors (CAIs) of the Sulfonamide Type,
Acetazolamide AAZ 1, Dichlorophenamide DCP 2a
aPhenol 3 and the polyamines investigated here as novel CAIs include
spermine 4, spermidine 5,N,N0-bis-(3-aminoethyl)-1,3-propanediamine
6 and triethylenetetramine (trien) 7. pKa values for the various amine
functions of spermine and spermidine are also provided.1
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IV was the most susceptible isoform to be inhibited
(KI of 112nM).ManyotherCA isoformswere inhibited
by 5 with inhibition constants in the low micromolar
range such as hCA I, hCA II, hCAVA, hCAVB, hCA
VI, hCA VII, hCA IX, and hCAXIV (KIs in the range
of 1.00-1.44 μM). Isoforms hCA III, mCA XIII, and
mCAXV showed moderate inhibition with spermidine
(KIs of 10.0-11.6 μM), whereas hCAXII was the least
inhibited isozyme, with KI of 44.1 μM (Table 1).
(iii) The length of the polyamine chain seems to be an
important factor governing SAR for this class of
CAIs reported here. This is the reason why we
investigated polyamines with a linear chain incorpor-
ating 4-14 atoms in their molecules, i.e., from ethyl-
enediamine to spermine. The simplest polyamine,
ethylenediamine (H2NCH2CH2NH2), did not act as
a CAI against any of the 13 investigated isoforms,
as mentioned above (data not shown). However,
its 1-naphthyl derivative 12 showed significant CA
inhibitory properties against isoforms CA III-XV,
while being a rather weak hCA I and II inhibitor
(KIs of >500 μM against hCA I and of 103 μM
against hCA II). Indeed, the remaining isoforms were
inhibited, with KIs in the range of 48 nM to 0.64 μM
by this simple compound (Table 1). Diamines 9 and
10 as well as the triamine 11 also showed appreciable
inhibitory activity against all tested isozymes, simi-
larly to the longer polyamines 4 (14 atoms in the
chain) and 5 (10 atoms in the chain). hCA I and II
were less inhibited by these amines (KIs of 11.0-
415 μM), whereas the remaining isoforms were
more susceptible to inhibition, with KIs of 44 nM to
0.74 μM (for 9 and 10) and of 10.1-117 μM in the
case of 11 (which was the least active inhibitor among
the three compounds discussed here, i.e., 9-11). The
influence of the polyamine chain on the CA inhibi-
tory properties can also be observed by comparing
the synthesized derivatives 14-20, which, as the
Table 1. Inhibition Data with the Clinically Used Sulfonamides Acetazolamide 1, Dichlorophenamide 2, As Well As Phenol 3 and Polyamines 4-21,
against CA Isozymes I-XIV by a Stopped-Flow Technique Monitoring the CO2 Hydration Reaction27
KI (μM)
b
isozymea 1 2 3 4 5 6 7
hCA I 0.250( 0.01 1.20( 0.02 10.2 ( 0.008 231( 4 1.40( 0.06 115( 5 100( 4
hCA II 0.012( 0.001 0.038( 0.003 5.5 ( 0.01 84( 2 1.11( 0.02 75( 3 64( 1.4
hCA III 200( 9 680( 23 2.7 ( 0.03 167( 8 11.5( 0.01 63( 2.5 48( 2.1
hCA IV 0.074( 0.002 15( 0.09 9.5 ( 0.4 0.010( 0.001 0.112( 0.005 44( 2.1 35( 0.7
hCA VA 0.063 ( 0.004 0.63( 0.02 218 ( 10 0.84( 0.03 1.22( 0.01 50( 1.8 38( 1.1
hCA VB 0.054( 0.002 0.021 ( 0.001 >500 0.83( 0.04 1.44( 0.06 59( 2.1 49( 2.4
hCA VI 0.011 ( 0.001 0.079( 0.006 208 ( 11 0.99( 0.04 1.41( 0.05 53( 2.5 43( 0.9
hCA VII 0.0025( 0.001 0.026 ( 0.002 >500 0.71( 0.06 1.23( 0.05 58( 1.4 45( 0.8
hCA IX 0.025 ( 0.003 0.050( 0.004 8.8 ( 0.09 13.3( 0.62 1.37( 0.07 48( 2.4 39( 1.3
hCA XII 0.0057( 0.001 0.050 ( 0.002 9.2 ( 0.7 27.6( 1.8 44.1( 3.1 68( 3.6 57( 2.0
mCA XIII 0.017( 0.002 0.023( 0.001 >500 22.6( 1.1 11.6( 0.2 66( 2.9 52( 1.1
hCA XIV 0.041( 0.004 0.345 ( 0.05 11.5 ( 0.7 0.86( 0.02 1.00( 0.03 36( 1.2 12.1( 0.9
mCA XV 0.072( 0.03 0.095( 0.004 10.5 ( 0.6 74( 3.2 10.0( 0.54 66( 1.4 59( 2.0
isozyme 8 9 10 11 12 13 14
hCA I >500 12.6( 0.9 13.3( 1.2 415( 12 >500 12.3( 0.4 136( 9
hCA II 11.2 ( 0.09 34.4( 1.2 11.0( 0.9 118( 9 103 ( 9 1.13 ( 0.08 11.3( 0.10
hCA III 0.52 ( 0.02 0.60( 0.02 0.50( 0.02 117( 8 0.42 ( 0.02 11.6( 0.02 11.5( 0.08
hCA IV 0.053 ( 0.003 0.45( 0.01 0.052( 0.001 116( 10 0.058 ( 0.003 0.018( 0.002 0.116( 0.003
hCA VA 0.047 ( 0.001 0.61( 0.04 0.044( 0.002 110 ( 4 0.048 ( 0.002 1.03( 0.02 1.26( 0.05
hCA VB 0.71 ( 0.05 0.58( 0.05 0.54( 0.03 11.0( 0.9 0.061 ( 0.005 1.05( 0.03 1.05( 0.04
hCA VI 0.78 ( 0.06 0.72( 0.10 0.74( 0.06 11.5( 1.1 0.64 ( 0.03 0.11 ( 0.009 1.10( 0.02
hCA VII 0.73 ( 0.04 0.44( 0.03 0.42( 0.01 12.1( 0.7 0.36 ( 0.02 0.10( 0.007 1.09( 0.06
hCA IX 0.31 ( 0.009 0.41( 0.01 0.38( 0.02 10.6( 0.2 0.51 ( 0.04 0.12( 0.006 11.4( 0.9
hCA XII 0.52 ( 0.02 0.37 ( 0.03 0.45( 0.02 11.4( 1.1 0.38 ( 0.01 0.19( 0.01 10.2( 1.0
mCA XIII 0.58 ( 0.02 0.69( 0.05 0.63 ( 0.05 11.5( 0.5 0.62 ( 0.03 10.2( 0.7 12.6( 1.2
hCA XIV 0.74 ( 0.04 0.64( 0.02 0.50( 0.04 10.1 ( 0.8 0.59 ( 0.02 1.03( 0.04 6.7( 0.05
mCA XV 0.76 ( 0.05 0.66( 0.06 0.65( 0.02 105( 7 0.57 ( 0.05 0.78( 0.09 110( 3
15 16 17 18 19 20 21
hCA I >500 137( 7 122( 5 >500 >500 >500 >500
hCA II 107 ( 5 110( 4 112( 7 >500 >500 >500 121 ( 7
hCA III 112 ( 4 132( 6 96( 3 >500 >500 >500 128 ( 8
hCA IV 104 ( 2 103( 2 108( 4 309 ( 12 >500 >500 12.3 ( 0.9
hCA VA 125 ( 6 131( 4 62( 1.4 416 ( 18 >500 >500 106 ( 4
hCA VB 103 ( 3 107( 3 54( 0.9 401 ( 15 >500 >500 107 ( 3
hCA VI 104 ( 3 114( 5 156( 11 >500 >500 >500 109 ( 6
hCA VII 107 ( 6 108( 1 108( 9 >500 >500 >500 1.24 ( 0.03
hCA IX 124 ( 3 144( 7 117( 8 >500 >500 >500 12.2 ( 0.5
hCA XII 175 ( 9 165( 9 112( 5 >500 >500 >500 21.5 ( 1.1
mCA XIII 179 ( 11 136( 4 131( 8 >500 >500 >500 127 ( 7
hCA XIV 85 ( 2 115( 5 125( 4 >500 >500 >500 34 ( 0.4
mCA XV >500 236( 14 104( 2 >500 >500 >500 110 ( 5
a h = human; m = murine isozyme. bMean ( standard error (n= 3, from three different assays).
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parent polyamines from which they were prepared,
possess scaffolds of 10-14 atoms. Thus, the spermine
derivative 14 showed good CA inhibitory pro-
perties against many isoforms (e.g., hCA IV, hCA
VA, hCA VB, hCA VI, and hCA VII), whereas the
shorter analogue 17 was 1-2 orders of magnitude a
weaker inhibitor compared to 14. The length of the
(substituted)aliphatic scaffold incorporating from two
to four amine functionalities is thus one of the principal
factors influencingCAinhibitoryactivityofpolyamines.
(iv) The number of amine moieties in the polyamine
scaffold, and their substitution pattern seems to be
the second critical factor influencing SAR in this new
class of CAIs. We included in the study compounds
possessing from two to four amine moieties. The
simplest derivatives were the unsubstituted poly-
amines 4-7 and 9-11, which incorporate only NH
or NH2 functionalities. However we also included 8,
which is the hexamethylated analogue of 7, 13,
together with derivatives 14-20, which have the
primary, terminal amine, both the primary and sec-
ondary amine groups, and/or only the secondary
amine groups derivatized by means of trifluoroacetyl
or Boc moieties. It may be seen that 8 was a better
CAI against all isoforms (except hCA I) compared to
the nonmethylated lead 7. Themonoderivatized sper-
mine derivative 13 was also generally more effective
as a CAI compared to spermine 4, except the activity
against hCA IV, the case for which the two com-
pounds showed similar activity (inhibition constants
of 10-18 nM). In fact, 13 was one of the most
promising CAIs detected so far in this work. Against
hCA II, 13 was 74 times a better inhibitor compared
to spermine 4, against hCA III this factor was of 14.4,
whereas against mCA XV of 94.8. Compound 21,
which incorporates trifluoroacetyl derivatized amino
group (present in 12), did show some CA inhibi-
tory properties but highly reduced compared to 12.
Indeed, 21 inhibited efficiently only hCA VII (KI of
1.24 μM). Thus, the presence of at least one terminal
free amino group seems to be essential for inducing
strongCA inhibitory properties to thesemolecules. By
examining derivatives 14-20, in which the primary
and/or secondary amine moieties of spermine 4, tetra-
mine 6, or trien7havebeenderivatized, this conclusion
is very much reinforced. It is interesting to note that
derivative 14, which has only the primary, terminal
amino moieties derivatized, still maintained some
good levels of CA inhibitory activity, with KIs in the
range of 0.116-1.26 μM against isoforms hCA IV,
VA, VB, VI, and VII, whereas for the remaining ones
the inhibition was less strong. For the shorter deriva-
tives 17-20 incorporating the same derivatization
pattern discussed above, the CA inhibitory properties
were very much decreased compared to the parent
amines 6 and 7, which demonstrates that not much
derivatization of the amine moieties in polyamines is
compatible with strong CA inhibitory properties.
(v) The investigated polyamines 4-21 showed an inhibi-
tion profile against the differentCA isozymes different
from that of other classes of CAIs. This clearly reflects
the factors discussed above, which are controlling
activity, i.e., the length of the polyamine chain, the
number of amine functionalities present in it, and their
derivatization pattern, the charged character (as am-
monium cations) of thesemolecules, the presence of at
least one bulky terminal moiety derivatizing one of
the primary amino groups, etc. Indeed, the different 13
CA isoforms were inhibited with potencies ranging
from the low nanomolar to the millimolar by poly-
amines and their derivatives, which are notably dif-
ferent from those of sulfonamide CAIs, such as 1, 2, or
phenol 3 (Table 1). But themost intriguing findingwas
the high affinity of many polyamines for CA IV, an
extracellular isoformassociated to plasmamembranes
by phosphatidylinositol-glycan linkages, a feature
unique only to this isoform among the human CAs.
The most characteristic feature of the active site of this
isozyme is related to the presence of four cysteine
residues, which form two disulfide bonds, situated at
the entrance within the active site cavity (Cys 6-Cys
11G, and Cys 23-Cys 203, respectively), which are not
present in otherCAs.24a These residues occupy the same
region of the active site as the histidine residues in the
cytosolic isoforms, which are involved in the binding of
CAIs and CAAs.20-25 We hypothesize that this struc-
tural feature may explain the difference in affinity for
polyamine inhibitors of CA IV compared to other
isoforms. As the terminal part of the polyamine inhi-
bitor extends toward the exit of the active site cavity,
where is the region with the highest variability in amino
acid residues within these enzymes active sites,23-25 it is
envisageable that this new inhibition mechanism may
lead to compounds with a better isoform selectivity
compared to the simple derivatives investigated here, as
already observed for coumarin CAIs.23
X-ray Crystallography and Inhibition Mechanism of Poly-
amines. To better understand the inhibition mechanism of
Chart 2. Commercially Available Polyamines 8-13 and
Synthesized Derivatives 14-21 Used as CAIs in the Present
Work
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this new class of CAI, the polyamines, we resolved the X-ray
crystal structure (at a resolution of 2.0 A˚) of spermine 4
in adduct with the physiologically dominant CA isoform,
hCA II.
The crystallographic parameters and refinement statistics
for the hCA II-spermine adduct are shown in Table 2.
Inspection of the electron density maps (Figure 1) at various
stages of the refinement, showed features compatible with
the presence of one molecule of inhibitor 4 bound within the
active site (Figures 1-3). All spermine atoms have a clearly
defined electron density in the adduct, as shown in Figure 1,
where the electron density of water113 and of the amino acid
residue Gln92 are also included for reasons which will be
understood shortly. The polyamine 4 (which at the pH of 7.4
at which both the kinetic and crystallographic experiments
have been performed is a tetracation)1 adopts a coiled
conformation when bound to the enzyme active site, as
observed from Figures 1-3. Spermine was found bound
deep within the hCA II active site but not directly coordi-
nated to the metal ion. Indeed, the Zn(II) bound water/
hydroxide ion is observed both in the native hCA II and
hCA II-4 complex (Figure 1), spermine being anchored to
this nonprotein zinc ligand, in a complex manner, which is
reminiscent of the binding of phenol 3 to hCA II (the X-ray
crystal structure for the hCA II-phenol adduct has been
reported earlier).20f Indeed, the OHmoiety of phenol makes
a strong hydrogen bond (of 2.6 A˚) with the nonprotein zinc
ligand and aweaker one (of 3.2 A˚) with theNHof Thr199, as
shown schematically in Figure 4B. Spermine is anchored to
the Zn(II) bound water molecule/hydroxide ion similarly to
phenol 3 by means of a strong hydrogen bond of 2.8 A˚
involving one of its terminal ammonium groups (Figure 4A).
If the nonprotein zinc ligand is preponderantly the hydroxide
ion (as we think the situation to be at pH 7.4), one may
consider the interaction between it and the ammonium
moiety of spermine also as an ionic interaction. However,
there are no literature data regarding the interaction of
ammonium salts with negatively charged moieties present
in proteins. Furthermore, the same moiety of the inhibitor
(i.e., the terminal ammonium group) participates in a second
hydrogen bond (of 3.0 A˚) with the OH of Thr199 (and not
with its amide NH, as in the hCA II-phenol adduct). The
Zn(II) bound hydroxide ionmakes a hydrogen bondwith the
same OHmoiety of Thr199, which is conserved in all R-CAs
for which the X-ray crystal structure has been reported so
Table 2. Crystallographic Parameters and Refinement Statistics for the
hCA II-Spermine 4 Adduct
Data Collection Statistics
PDB accession number 3KWA
temperature (K) 100
wavelength (A˚) 1.5418
space group P21
unit-cell parameters (A˚, deg) a= 41.4, b= 42.1,
c= 72.2, β= 104.3
total no. of measured reflections 65214
no. of unique reflections 16497
resolution (A˚) 20.0-2.0
Rsym
a,d 4.8% (40.0%)
F2/σ(F2) 15.1 (4.0)
completeness (%) 99.3 (99.0)
Final Model Statistics
Rcryst (%)
b 23.3
Rfree(%)
c 28.5
residue nos. 1-261
no. of protein atoms
(including alternate conformations)
2045
no. of inhibitor atoms 14
no. of H2O molecules 179
rmsd for bond lengths (A˚), angles (deg) 0.015, 1.7
Ramachandran statistics (%):
most favored, additionally allowed,
and generously allowed regions
88.0, 11.6, 0.5
B factors (A˚2): average, protein,
inhibitor, solvent
27.0, 14.9, 34.0, 32.1
aRsym=
P
|I- ÆI æ|/
P
ÆI æ. b Rcryst= (
P
|Fo|- |Fc|/
P
|Fobs|) 100 .
cRfree is calculated in same manner as Rcryst, except that it uses 5% of
the reflection data omitted from refinement. dValues in parentheses
represent highest resolution shell.
Figure 1. The electron density 2Fo - Fc map at 1σ of spermine
(in yellow) bound within the hCA II active site (in two different
orientations, A and B). The Zn(II) ion of the enzyme, its three
histidine ligands (His94, 96, and 119), residues involved in the binding
of the inhibitor (Thr199, Thr200, Pro201, andGln92) as well as three
water molecules participating in hydrogen bonds/van der Waals
contacts with the inhibitor are also shown in A (as electron density).
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far, in the native enzyme and in its complexes with various
classes of inhibitors.24-27 This hydrogen bond (Zn-OH-----
HO-Thr199) is also present in the wild type enzyme and,
together with the hydrogen bond between the carboxylate of
Glu106 and the OH of Thr199, is thought to have a role in
properly orienting the zinc-bound hydroxide for the nucleo-
philic attack on the substrates of these enzymes (CO2, esters,
coumarins, etc).11,23-27 Thus, an important novelty of this
work is that we observed for the first time the anchoring
of a primary amine (as charged ammonium moiety) to the
zinc-bound solvent molecule of CA, through a network of
hydrogen bonds involving also the conserved amino acid
residue Thr199. Although this binding has some similarity
with that of phenol to the CA active site, there are also
important differences between the anchoring of phenol and
spermine (Figure 4A,B), as discussed above.
The two secondary amine moieties of spermine (both of
them positively charged as ammonium cations at pH 7.4)1 do
Figure 2. Stereoview of the binding of spermine (yellow) to the
hCA II active site. The Zn(II) ion (violet sphere), ith three protein
ligands (His94, 96 and 119) and nearby amino acid residues 92 and
199-201 are also shown.
Figure 3. Detailed interactions inwhich spermine (in yellow) participates when bound to the hCA II active site. The zinc ion (violet sphere), the
watermolecule coordinated to it (small red sphere), and its three protein ligands (His94, 96, and 119, in green), aswell as amino acids involved in
the binding of spermine (Thr199, Thr200, Pro20,1 and Gln92, in gold) are also shown. The protein scaffold is in green (ribbon diagram).
Figure 4. (A) Schematic representation of interactions in which
spermine 4 (as tetracation) participates when bound to the hCA II
active site. Figures represent distances (in A˚). Hydrogen bonds are
represented as dashed lines. In bold are shown two clashes involving
some carbon atoms (C5 and C7) of the spermine scaffold with a
water molecule (Wat113) and Gln92. The nonprotein zinc ligand is
represented as a hydroxide ion, which should be the preponderant
species at the pH at which the experiments were done (7.5). (B)
Schematic representation of the binding of phenol 320f to hCA II.
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not interact with amino acid residues of the enzyme active
site (Figures 3 and 4A). The central aliphatic fragment
(CH2)4 of spermine makes several weak van der Waals
contacts with various amino acid residues (data not shown)
and water molecules from the active site cavity, of which two
are clashes with water113 (of 3.1 A˚) and with the CONH2
nitrogen ofGln92 (of 2.9 A˚), as observed inFigures 1 and 4A.
These clashesmay explain the rather weak inhibitory activity
of spermine against hCA II, with a KI of 84 μM. Both
propylene fragments present in spermine do not participate
in any relevant contact with amino acid residues/water
molecules from the enzyme active site.However, the terminal
primary amine moiety (similarly to the one anchored to the
zinc-bound water molecule discussed above) participates in
several strong interactions with two amino acid residues
known to be involved in the binding of many types of
sulfonamide inhibitors,26,28-31 i.e., Thr200 and Pro201
(Figure 4A). Thus, three hydrogen bonds of 3.3, 3.3, and
2.9 A˚, respectively, have been evidenced between this ammo-
niummoiety of spermine and the CdO of Thr200, the OH of
the same amino acid residue, and the carbonyl oxygen of
Pro201. All these interactions probably stabilize the enzyme-
inhibitor adduct. However, the positively charged character
of this inhibitor (a tetracation), the two clashes mentioned
above, and the fact that it binds deep within the CA active
site (without interacting with the more external part of the
cavity) may explain the fact that spermine is only a weak-
-medium potency hCA II inhibitor (KI of 84 μM). Indeed,
there may be electrostatic repulsions between the tetracation
and the metal ion from the bottom of the active site cavity,
even if between the two there is the zinc-bound hydroxide,
negatively charged ion. Furthermore, the inhibitor binds
deep within the active site cavity, making strong contact
with amino acid residues in the vicinity of the Zn(II) ion
(Thr199, Thr200, and Pro201), without any contact with
amino acid residues toward the exit of the cavity, as
observed in Figure 5, where the hCA II-spermine adduct
is superposed on the hCA II-phenol20f and hCA II-2-
hydroxycinnamic acid23b adducts. These crystallographic
data are in very good agreement with the solution data
discussed above, as they show that there is enough space for
longer or shorter polyamine analogues to bind within the
active site. They also support our observations that small
compact groups can derivatize the various amine function-
alities of the polyamine, without the significant loss of CA
inhibitory activity, but that the best inhibitors may be those
possessing a terminal free amino moiety and eventually
another terminal derivatized moiety, as for example in 13
(or 12). Assuming that the long chain present in 13will bind
to theCAactive site as spermine 4, the crystallographic data
show that there is enough space for the bulky terminal
moiety (as the 1-naphthylacetamido one present in 13)
to be accommodated toward the exit of the active site
cavity, which may lead to stronger inhibitors from this
class. Indeed, the monoderivatized spermine 13 was a 74
times better hCA II inhibitor compared to spermine 4,
which is accounted for very well by our crystallographic/
solution data.
Figure 5. Superimposition of the spermine 4 (yellow), phenol 3 (magenta),20f and trans-2-hydroxycinnamic acid23b 22b (violet) adducts with
hCA II. The Zn(II) ion is the violet sphere. The Zn(II) histidine ligands as well as residues 92 and 199-201 involved in the binding of inhibitors
are also evidenced. One terminal amino moiety of spermine (which hydrogen bonds the nonprotein zinc ligand) is fully superimposed on
the phenol OH moiety, which is interacting with the same group of the enzyme. The phenyl moiety of phenol and the organic scaffold
of spermine are not superimposable. 2-Hydroxycinnamic acid 22b (in violet),23b the hydrolysis product of coumarin 22a binds toward the exit of
the active site and is not superposable with phenol 3 and spermine 4.
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Returning to the comparison of this novel bindingmode for
aCAI, it should be noted that 2-hydroxycinnamic acid 22b,23b
the hydrolysis product of coumarin 22a (in violet) binds
toward the exit of theCAactive site and is not superimposable
with phenol 3 and spermine 4, which are observed deep within
the active site, toward the bottom of the cavity. This has
important consequences for the drug design of CAIs based on
thesenew leadmolecules, the polyamines. Indeed, it is possible
that by derivatization of the terminal amino moiety of sperm-
ine (or structurally related polyamines), more potent CAIs
can be obtained, as there is enough space in the enzyme cavity
to accommodate different moieties in the active site region
where this terminal amino moiety binds (Figure 4 and 5).
Another aspect of the future drug design strategies based on
polyamines as lead molecules is based on the great difference
in inhibitory capacity of the polyamines investigated here:
small variations in the number of atoms of the chain as well as
the number of heteroatoms from their molecules, strongly
influence the CA inhibitory activity of these polyamines, as
discussed extensively above.
Conclusions
We investigated whether polyamines such as spermine,
spermidine, and some of their synthetic congeners possessing
chains of 4-14 atoms, 2-4 of which are nitrogens, interfere
with the CA isoforms’ catalytic activity, knowing that amines
and amino acids act as activators of these zinc enzymes. We
report here that polyamines constitute a novel class of CAIs,
inhibiting the different CA isozymes with efficiency from the
low nanomolar to millimolar range. For example, spermine
showed a KI of 10 nM against CA IV, is a submicromolar
inhibitor of CA VA, CA VB, CA VI, CA VII, and CA XIV,
inhibits CA IX,XII, andXII in the range of 13-27 μM,and is
less effective as an inhibitor of CA I, II, and III (KIs of 84-
231 μM). Spermidine, N,N0-bis-(3-aminoethyl)-1,3-propane-
diamine and triethylenetetramine (trien), similarly to sperm-
ine, inhibited all mammalian isozymes with very different
inhibition profiles. A detailed SAR has been obtained against
13 different CA isoforms by analyzing the length of the
aliphatic chain in the polyamine molecule, the number of
amine functionalities, their nature (primary, secondary, or
tertiary amine) and derivatization. The main SAR features
have been delineated very clearly, being observed that effec-
tive CAIs may be obtained incorporating at least 7 atoms in
the chain, that at least one freeNH2moiety should be present,
whereas the distal, terminal one may be functionalized even
withbulkier groups. TheX-ray crystal structure of theCAII-
spermine adduct allowed us to understand the inhibition
mechanism of CAs with polyamines and the SAR obtained
by solution assays. Spermine was observed to be anchored to
thenonprotein zinc ligand (ahydroxide ionatpH7.4) through
a network of hydrogen bonds involving Thr199. Further-
more, its various amine moieties made several hydrogen
bonds and van der Waals contact with amino acid residues
Thr200 and Pro201, which further stabilized the adduct but
clashes with a water molecule and Gln92 have also been
evidenced. Spermine thus binds very differently compared to
sulfonamides, phenols, or coumarins within the CA active
site, allowing thus for obtaining CAIs with diverse inhibition
profiles and selectivity for various isoforms. Finally, it should
be noted that extrapolating the aboveKI values based on pure
CA proteins to conditions in vivo cannot be done directly.
Further work is needed to optimize these various CAIs
described here to obtain compounds for in vivo studies and
to develop novel drugs from these leads.
Experimental Protocols
Chemistry. Sulfonamides 1 and 2, phenol 3, and amines 4-7
are commercially available, highest purity grade reagents
from Sigma-Aldrich (Milan, Italy). All CA isozymes were
recombinant ones, obtained in house as reported earlier.20,22,23
Anhydrous solvents and all reagents were purchased from
Sigma-Aldrich and Alfa Aesar. All reactions involving air- or
moisture-sensitive compoundswere performed under a nitrogen
atmosphere using dried glassware and syringes techniques to
transfer solutions. Infrared (IR) spectra were recorded as thin
films or nujol mulls on NaCl plates and are expressed in
ν (cm-1). Nuclear magnetic resonance (1H NMR, 13C NMR)
spectra were determined in DMSO-d6 and were recorded were
recorded at 400 MHz on a Bruker Advance III instrument.
Chemical shifts (δ scale) are reported in parts per million
(ppm), and the coupling constants (J) are expressed in hertz
(Hz). Splitting patterns are designated as follows: s, singlet; d,
doublet; t, triplet; q, quadruplet; m, multiplet; bs, broad singlet;
dd, double doublet. The assignment of exchangeable protons
(OH andNH) was confirmed by the addition of D2O. Analytical
thin-layer chromatography (TLC) was carried out on Merck
silica gel F-254 plates. Flash chromatography purifications were
performed onMerck Silica Gel 60 (230-400mesh ASTM) as the
stationary phase. The purity has been determined by means of
analyticalHPLC,performedona reversedphaseC18Bondapack
column,with a BeckmanEM-1760 instrument.HPLC confirmed
a purity of >99.5% for the compounds investigated here.
Synthesis of N1,N12-Bis(trifluoroacetyl)spermine Bis Trifluoro-
acetate 14.32
Spermine 4 (1.0 g, 1.0 equiv) was dissolved in acetonitrile
(20 mL), and the clear solution was treated with ethyltrifluoro-
acetate (3.5 g, 5.0 equiv), water (0.2 g, 2.5 equiv), and refluxed
overnight. Volatiles were removed in vacuo to give a light-brown
solid that was washed with DCM (4  10 mL) and then purified
by silica gel column chromatography elutingwith 5%NH4OH in
EtOHtoafford the title compound1 as awhite solid in 93%yield.
N1,N12-Bis(trifluoroacetyl)spermine Bis Trifluoroacetate (14).
mp 197-199 C (lit.32 195-198 C); silica gel TLC Rf 0.50 (25%
NH4OH/EtOH); νmax (KBr) cm
-1, 3296, 1715, 1698. δH (400
MHz, DMSO-d6) 1.65 (4H, brm), 1.86 (4H, m), 2.96 (8H, brm),
3.30 (4H,m), 8.57 (4H,br, 2NH2, exchangewithD2O), 9.63 (2H,
br 2NH). δC (100MHz, DMSO-d6) 159.5 (q, J 32, CF3COO-),
157.6 (q, J 36, CF3CON), 119.5 (q, J 156,CF3CO), 116.0 (q, J 124,
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CF3CO), 47.0, 45.4, 37.5, 26.0, 23.6. δF (376 MHz, DMSO-d6)
-74.38 and-74.37 (NHCOCF3), -73.6 and-73.5 (CF3COO).
Synthesis of N1,N12-Bis(trifluoroacetyl)-N4,N8-bis(t-butoxy-
carbonyl)spermine 15.33
To a solution of N1,N12-bis(trifluoroacetyl)spermine bis tri-
fluoroacetate 14 (1.65 g, 1.0 equiv) and triethylamine (1.61 g,
6.0 equiv) in dry THF (20 mL) was slowly added di-tert-butyl
dicarbonate (1.74 g, 3.0 equiv) and the solution was stirred
overnight at rt. The reaction was quenched with water (100 mL)
and extracted with ethyl acetate (4  20 mL). The combined
organic layers were dried over Na2SO4, filtered, and concentrated
in vacuo to give a pale-yellow oil that was triturated with diethyl
ether to afford the title compound 2 as a white solid in 78% yield.
N1,N12-Bis(trifluoroacetyl)-N4,N8-bis(t-butoxycarbonyl)sper-
mine (15).mp 108-110 C; silica gel TLC Rf 0.33 (1.5%MeOH/
DCM); νmax (KBr) cm
-1, 3288, 2994, 2972, 1730, 1660. δH (400
MHz, DMSO-d6) 1.41 (18H, s, 6  CH3), 1.42 (4H, brm), 1.72
(4H, m), 3.19 (12H, m), 9.40 (2H, br, 2  NH). δC (100 MHz,
DMSO-d6) 157.0 (q,
3JC-F 35), 154.8 (CO), 117 (q, JC-F 286),
79.3 (ipso), 46.9 (d), 45.0 (d), 38.0, 28.9 (CH3), 28.3 (d), 26.1 (d).
The spectra are in agreementwith reported data in the literature.33
Synthesis of N4,N8-Bis(t-butoxycarbonyl)spermine 16.33
N1,N12-Bis-(trifluoroacetyl)-N4,N8-bis(tert-butoxycarbonyl)-
spermine 15 (0.33 g) was treated with a solution (10 mL) of
MeOH/NH4OH (1/2 ratio) and the solution was stirred under
reflux overnight. Then the volatiles were removed under vacuo
to give a residue that was purified by silica gel column chroma-
tography eluting with an increasing amount of MeOH in DCM
from 10% to 40% to afford the titled compound 16 as a light-
brown oil in 65% yield.
N 4,N8-Bis(t-butoxycarbonyl)spermine (16). Silica gel TLC Rf
0.13 (25% NH4OH/EtOH); 3434, 1656. δH (400 MHz, D2O)
1.34 (9H, s, 6  CH3), 1.56 (4H, brs), 1.66 (4H, s, m), 2.69
(4H, m), 3.14 (8H, m). δC (100 MHz, D2O) 158.1 (CO), 81.9
(ipso), 47.3 (br), 44.7 (br), 39.4, 38.2, 28.4, 25.6 (br). The spectra
are in agreement with reported literature data.33
Synthesis of N1,N2-(2-(2,2,2-Trifluoroacetamido)ethyl)ethane-
1,2-diaminium Trifluoroacetate 19.32
Triethylenetetramine (1.0 g, 1.0 equiv) was dissolved in
acetonitrile (20 mL), and the clear solution was treated with
ethyltrifluoroacetate (4.9 g, 5.0 equiv) and water (0.3 g,
2.5 equiv) and refluxed overnight. Volatiles were removed in
vacuo to give a pale-yellow solid that was triturated with DCM
to afford the title compound 19 as a white solid in 82% yield.
N1,N2-(2-(2,2,2-Trifluoroacetamido)ethyl)ethane-1,2-diami-
nium Trifluoroacetate. mp 156-1157 C; νmax (KBr) cm-1,
3264, 2988, 1718, 1665. δH (400MHz,DMSO-d6) 1.97 (2H,m),
3.05 (4H, m), 3.14 (4H, m), 3.55 (4H, m), 8.93 (4H, brm, 2 
NH2), 9.69 (2H, t, J 5.2) 2  NH). δC (100 MHz, DMSO-d6)
159.6 (q, J 32, CF3COO
-), 157.8 (q, J 36, CF3CON), 119.7
(q, J 156, CF3CO), 114.0 (q, J 122, CF3CO), 46.2, 44.9, 36.7,
23.4. δF (376 MHz, DMSO-d6) -74.4, -74.6.
Synthesis of Di-tert-butylethane-1,2-diylbis(2-(2,2,2-trifluoro-
acetamido)ethylcarbamate 20.33
To a solution of N1,N2-(2-(2,2,2.trifluoroacetamido)ethyl)-
ethane-1,2-diammonium trifluoroacetate 19 (0.2 g, 1.0 equiv)
and triethylamine (0.21 g, 6.0 equiv) in dry THF (5 mL) was
slowly added di-tert-butyl dicarbonate (0.23 g, 3.0 equiv) and
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the solution was stirred overnight at rt. The reaction was
quenched with an aqueous saturated solution of NaHCO3
(50 mL) and extracted with DCM (320 mL). The combined
organic layers were dried overNa2SO4, filtered, and concentrated
in vacuo to give a white semisolid that was purified by silica gel
column chromatography eluting with 5% MeOH in DCM to
afford the titled compound 20 as a white solid in 82% yield.
Di-tert-Butylethane-1,2-diylbis(2-(2,2,2-trifluoroacetamido)-
ethylcarbamate (20).mp 160-162 C; silica gel TLCRf 0.10 (5%
MeOH/DCM); νmax (KBr) cm
-1, 3270, 2988, 2970, 1720, 1664;
δH (400MHz, DMSO-d6) 1.41 (18H, s, 6 CH3), 3.27 (12H, m),
9.50 (2H, br, 2  NH); δC (100 MHz, DMSO-d6) 157.2 (q, J 32,
CF3CON), 155.8 (CO), 116.2 (q, J 286,CF3CO), 79.8, 45.6, 38.6,
28.8, 27.8; δF (376 MHz, DMSO-d6) -74.4, -74.6.
Synthesis of N1,N3-bis(2-(2,2,2-trifluoroacetamido)ethyl)-
propane-1,3-diaminium trifluoroacetate 17.32
N,N1-Bis-(2-aminoethyl)1,3-propanediamine (1.0 g, 1.0 equiv)
was dissolved in acetonitrile (20 mL), and the clear solution
was treated with ethyltrifluoroacetate (4.4 g, 5.0 equiv), water
(0.3 g, 2.5 equiv), and refluxed overnight. Volatiles were removed
in vacuo to give a white solid that was triturated with DCM to
afford the title compound 17 as a white solid in 80% yield.
N1,N3-Bis(2-(2,2,2-trifluoroacetamido)ethyl)propane-1,3-dia-
miniumTrifluoroacetate (17).mp145-147 C; νmax (KBr) cm-1,
3277, 2982, 2976, 1725, 1661. δH (400 MHz, DMSO-d6) 1.97
(2H, m), 3.04 (4H, t, J 7.6), 3.14 (4H, t, J 6.0), 3.54 (4H, q, J 5.6),
8.93 (4H, brs, 2NH2, exchange withD2O), 9.69 (2H, t, J 5.2, 2
NH, exchange with D2O). δC (100MHz, DMSO-d6) 159.9 (q,
J 31, CF3COO
-), 157.6 (q, J 36, CF3CON), 119.5 (q, J 146,
CF3CO), 116.4 (q, J 129,CF3CO), 46.2, 44.9, 36.7, 23.3. δF (376
MHz, DMSO-d6) -73.6, -74.5.
Synthesis of Di-tert-butylpropane-1,3-diylbis(2-(2,2,2-trifluoro-
acetamido)ethylcarbamate18.33
To a solution ofN1,N3-bis(2-(2,2,2-trifluoroacetamido)ethyl)-
propane-1,3-diammonium trifluoroacetate 17 (0.2 g, 1.0 equiv)
and triethylamine (0.21 g, 6.0 equiv) in dryTHF (3mL)was slowly
added di-tert-butyl dicarbonate (0.23 g, 3.0 equiv) in dry THF
(2.0 mL) and the solution was stirred overnight at rt. The reaction
was quenched with an aqueous saturated solution of NaHCO3
(50 mL) and extracted with DCM (3  20 mL). The combined
organic layers were dried over Na2SO4, filtered, and concentrated
in vacuo to give a white semisolid that was triturated from diethyl
ether toafford the titled compound18as awhite solid in 87%yield.
Di-tert-butylpropane-1,3-diylbis(2-(2,2,2-trifluoroacetamido)-
ethylcarbamate (18).mp 148-150 C; silica gel TLCRf 0.22 (5%
MeOH/DCM); νmax (KBr) cm
-1, 387, 2974, 2943, 1718, 1676.
δH (400 MHz, DMSO-d6) 1.42 (18H, s, 6 CH3), 1.69 (2H, m),
3.15 (4H, brm), 3.28 (8H,m). δC (100MHz,DMSO-d6) 157.4 (q,
J 36, CF3CON), 155.4 (CO) 116.0 (q, J 286,CF3CO), 79.6, 45.5,
44.8, 38.6, 28.9, 27.8. δF (376 MHz, DMSO-d6) -74.4, -74.6.
Synthesis of 2,2,2-Trifluoro-N-(2-(naphthalen-1-ylamino)-
acetamide 21.32
N1-Naphthalen-1-yl)ethane-1,2-diamine dihydrochloride (0.5 g,
1.0 equiv) was suspended in acetonitrile (10 mL) and treated with
ethyltrifluoroacetate (0.69 g, 5.0 equiv), water (0.04 g, 2.5 equiv),
and DIPEA (0.55 g, 2.2 equiv) and refluxed overnight. Volatiles
were removed in vacuo to give a sticky oil that was triturated with
DCM to afford the title compound 21 as a brown solid in 86%
yield.
2,2,2-Trifluoro-N-(2-(naphthalen-1-ylamino)acetamide (21).
mp 118-120 C; silica gel TLC Rf 0.37 (5% MeOH/DCM);
νmax (KBr) cm
-1, 3306, 2877, 1727, 1672. δH (400 MHz,
DMSO-d6) 3.42 (2H, q, J 5.6), 3.54 (2H, q, J 8.0), 6.32 (1H, t,
J 5.6, NH, exchange with D2O), 6.63 (1H, d, J 7.6), 7.16 (1H, d,
J 8.0), 7.35 (1H, t, J 8.0), 7.46 (2H, m), 7.80 (1H, d, J 8.0), 8.12
(1H, d, J 7.6), 9.64 (1H, t, J 5.6). δC (100 MHz, DMSO-d6)
157.0 (q, J 36, CF3CON), 144.5. 135.0, 128.9, 127.7, 126.6,
125.0, 123.9, 122.4, 117.0 (q, J 286,CF3CO), 116.7, 103.7, 42.6,
39.1. δF (376 MHz, DMSO-d6) -74.4.
CA Inhibition.AnApplied Photophysics stopped-flow instru-
ment was used for assaying the CA catalyzed CO2 hydration
activity.27 Phenol red (at a concentration of 0.2mM)was used as
indicator, working at the absorbance maximum of 557 nm, with
20 mM Hepes (pH 7.5) as buffer, and 20 mM Na2SO4 (for
maintaining a constant ionic strength), following the initial rates
of the CA-catalyzed CO2 hydration reaction for a period of
10-100 s. The CO2 concentrations ranged from 1.7 to 17 mM
for the determination of the kinetic parameters and inhibition
constants (five different substrate concentrations were used).
For each inhibitor, at least six traces of the initial 5-10% of the
reaction were used for determining the initial velocity. The
uncatalyzed rates were determined in the same manner and
subtracted from the total observed rates. Stock solutions of
inhibitor (0.1 mM) were prepared in distilled-deionized water,
and dilutions up to 0.01 nMwere done thereafter with distilled-
deionized water. Experiments were done using six different
inhibitor concentrations, varying from 100 μM to 0.1 nM.
Inhibitor and enzyme solutions were preincubated together for
15 min to 24 h at room temperature (15 min) or 4 C (all other
incubation times) prior to assay, in order to allow for the
formation of the E-I complex or for the eventual active site
mediated hydrolysis of the inhibitor. Data reported in Table 1
show the inhibition after 15 min incubation, as there were no
differences of inhibitory power when the enzyme and inhibitors
were kept for longer periods in incubation.1 The inhibition
constants were obtained by nonlinear least-squares methods
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using PRISM 3, as reported earlier,20,22,23 and represent the
mean from at least three different determinations.
Crystallization, X-ray Data Collection, and Refinement.Crys-
tals of the complex between hCA II and spermine 4 were
obtained by using the hanging-drop method for cocrystallizing
the protein with the ligand, as previously described.20 Drops
containing 5 μL of 20 mg/mL hCA II in 50 mM Tris-HCl,
buffer, pH7.4, weremixedwith 5 μLof precipitant buffer (2.4M
(NH4)2SO4 in 50 mM Tris-HCl, pH 7.4, and 1 mM sodium
4-(hydroxymercury) benzoate) with added 5 mM spermine 4
and equilibrated over a reservoir of 1mLof precipitant buffer. A
monochromatic experiment at the Cu R wavelength was per-
formed on a crystal of hCA II grown in the presence of 4 by the
rotation method on a PX-Ultra sealed-tube diffractometer
(Oxford Diffraction) at 100 K. The crystal belonged to space
group P21 (a=41.4; b=42.1; c=72.2; β=104.3). Data were
processed with CrysAlis RED (Oxford Diffraction 2006).28 The
structure was analyzed by difference Fourier technique, using
the PDB file 1CA225b as starting model. The refinement was
carried out with the programREFMAC529model building, and
map inspections were performing using the COOT program.30
The correctness of the stereochemistry was checked using the
program PROCHECK.31 The refinement statistics of the final
model of the hCA II-spermine complex are shown in Table 2.
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